Josu de la Fuente/imperial.nhs.uk
Apr 5, 2026, 17:42
Josu de la Fuente: Real World Data Shows Significant Risk of Subsequent HCT in SCD and Thalassemia
Josu de la Fuente, Consultant Paediatric Haematologist Director Blood and Marrow Transplant Programme at Imperial College Healthcare NHS Trust, shared a post on LinkedIn:
“Real-world data confirms a small but significant risk of the need for a subsequent HCT with no plateau over time in sickle and thalassaemia.
Real world data from HWP of EBMT presented today.”
Stay updated with Hemostasis Today.
-
Oct 8, 2026, 14:17Sudhanshi Raina: Predicting Germline Mutations in Aplastic Anemia Using Telomere Length
-
Oct 8, 2026, 14:10Rebecca Akpeloo: PE as an Overlooked Threat in Sickle Cell Disease
-
Oct 8, 2026, 14:05Christina Pohlman: World Thrombosis Day – Raising Awareness of DVT
-
Oct 8, 2026, 13:59Patience Nkabe Odey: What Drives Rhesus D Screening Uptake Among Pregnant Women?
-
Oct 8, 2026, 13:50Todd Rice: ECMO at the Intersection of Anticoagulation and Respiratory Failure
-
Oct 8, 2026, 13:35Manuel Monreal: Why IVC Filter Retrieval Matters for VTE Outcomes
-
Oct 8, 2026, 12:53Hellen Ishikawa-Ankerhold: PhD and Postdoctoral Positions in Advanced Microscopy and Immunothrombosis at LMU Munich
-
Oct 8, 2026, 12:45Pedro Perez: World Thrombosis Day 2026 – Raising Awareness of Women’s VTE Risk
-
Oct 8, 2026, 12:20Berrin Gunaydin: Functional Biomarkers of Iron Deficiency in Pregnancy